



## CLAIM AMENDMENTS

1. (original) A compound of formula PQ:



2. (original) A compound according to claim 1, of formula P or Q:



3. (original) (1*S*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine according to claim 1.


4. (original) (1*R*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine according to claim 1.

5. (original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to any of claims 1 to 4.


6. (original) A tablet or capsule according to claim 5.

7. (original) A method for treating CNS disorders in a human, the method comprising administering to a person in need of treatment for a CNS disorder, a therapeutically effective amount of:

- (a) (1*R*,4*S*)-*trans* 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine



- (b) (1*S*,4*R*)-*trans* 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine



- (c) a mixture of **P** and **Q**; or  
 (d) a pharmaceutically acceptable salt thereof.

8. (original) The method according to claim 7, wherein the CNS disorder is a mood disorder.

9. (original) The method according to claim 8, wherein the mood disorder is depression.

10. (previously amended) The method according to claim 7, wherein the CNS disorder is anxiety-related disorder.

11. (original) The method according to claim 10, wherein the anxiety-related disorder is obsessive compulsive disorder.

12. (original) The method according to claim 7, wherein the CNS disorder is a disruptive behavior disorder.

13. (original) The method according to claim 12, wherein the disruptive behavior disorder is one of attention deficit disorder (ADD) or attention deficit / hyperactivity disorder (ADHD).

14. (original) The method according to claim 7, wherein the CNS disorder is a sexual dysfunction.


15. (original) The method according to claim 7, wherein the CNS disorder is a substance abuse disorder.

16. (original) The method according to claim 7, wherein the CNS disorder is an eating disorder.


17. (original) A method according to claim 7, wherein the CNS disorder is premenstrual syndrome disorder.

18. (original) A method for the prophylaxis of migraine in a human, the method comprising administering to a person at risk or in need of therapy for a migraine, a therapeutically effective amount of a compound chosen from:

- (a) (1*R*,4*S*)-*trans* 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine




- (b) (1*S*,4*R*)-*trans* 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine




- (c) a mixture of **P** and **Q**; and
- (d) a pharmaceutically acceptable salt thereof.

19. (original) A method for treating psychoses in a human, the method comprising administering to a person in need of treatment for a psychoses, a therapeutically effective amount of:

- (a) (1*R*,4*S*)-*trans* 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine



- (b) (1*S*,4*R*)-*trans* 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine




- (c) a mixture of **P** and **Q** ; or
- (d) a pharmaceutically acceptable salt thereof, together with
- (e) a therapeutically effective amount of a D<sub>2</sub> antagonist, or a pharmaceutically acceptable salt thereof.

20. (original) The method according to claim 19, wherein the D<sub>2</sub> antagonist is olanzapine.


21. (cancelled)

22. (currently amended) A method for treating psychoses in a human, the method comprising administering to a person in need of treatment for a psychoses, a therapeutically effective amount of:

- (a) (1*R*,4*S*)-*trans* 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine



- (b) (1*S*,4*R*)-*trans* 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine




- (c) a mixture of **P** and **Q** ; or  
 (d) a pharmaceutically acceptable salt thereof, together with  
 (e) a therapeutically effective amount of an ~~atypical~~ antipsychotic agent, or a pharmaceutically acceptable salt thereof.


23. (previously amended) A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine, the process comprising:

- (a) reacting 4-(3,4-dichlorophenyl)-3,4-dihydro-1-naphthalenone with an excess of formic acid and formamide to provide *N*-[4-(3,4-dichloro phenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide; and  
 (b) hydrolyzing the *N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro naphthalen-1-yl]formamide with aqueous acid, yielding 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine.


24. (previously added) A compound of formula:




25. (previously added) A compound according to claim 24, of formula E:



26. (previously added) A compound according to claim 24, of formula F:



27. (previously added) A compound according to claim 24, of formula A, B, C, or D:



28. (previously added) (1*S*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide according to claim 24.

29. (previously added) (1*R*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide according to claim 24.

30. (previously added) (1*S*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide according to claim 24.

31. (previously added) (1*R*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide according to claim 24.

32. (previously added) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to any of claims 24 to 31.


33. (previously added) A tablet or capsule according to claim 32.

34. (previously added) A method for treating CNS disorders in a human, the method comprising administering to a person in need of treatment for a CNS disorder, a therapeutically effective amount of *N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide.


35. (previously added) A method according to claim 34, the method comprising administering to a person in need of treatment for a CNS disorder, a

therapeutically effective amount of:


- (a) (1*S*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide



- (b) (1*R*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide




- (c) (1*S*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide



- (d) (1*R*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide





- (e) a mixture of **A** and **B**;
- (f) a mixture of **C** and **D**; or
- (g) a pharmaceutically acceptable salt thereof.

36. (previously added) The method according to claim 34, wherein the CNS disorder is a mood disorder.

37. (previously added) The method according to claim 36, wherein the mood disorder is depression.

38. (previously added) The method according to claim 34, wherein the CNS disorder is anxiety-related disorder.

39. (previously added) The method according to claim 38, wherein the anxiety-related disorder is obsessive compulsive disorder.

40. (previously added) The method according to claim 34, wherein the CNS disorder is a disruptive behavior disorder.

41. (previously added) The method according to claim 40, wherein the disruptive behavior disorder is one of attention deficit disorder (ADD) or attention deficit / hyperactivity disorder (ADHD).

42. (previously added) The method according to claim 34, wherein the CNS disorder is a sexual dysfunction.

43. (previously added) The method according to claim 34, wherein the CNS disorder is a substance abuse disorder.


44. (previously added) The method according to claim 34, wherein the CNS disorder is an eating disorder.

45. (previously added) A method according to claim 34, wherein the CNS disorder is premenstrual syndrome disorder.


46. (previously added) A method for the prophylaxis of migraine in a human, the method comprising administering to a person at risk or in need of therapy for a migraine, a therapeutically effective amount of *N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide.

47. (previously added) A method according to claim 46, the method comprising administering to a person at risk or in need of therapy for a migraine, a therapeutically effective amount of a compound chosen from:


- (a) (1*S*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide




- (b) (1*R*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide

**B ;**

- (c) (1*S*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide

**C ;**

- (d) (1*R*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide

**D ;**


- (e) a mixture of **A** and **B**;  
 (f) a mixture of **C** and **D**; or  
 (g) a pharmaceutically acceptable salt thereof.

48. (previously added) A method for treating psychoses in a human, the method comprising administering to a person in need of treatment for a psychoses, a therapeutically effective amount of *N*-[4-(3,4-dichlorophenyl)-1,2,3,4-


tetrahydronaphthalen-1-yl]formamide.

49. (previously added) A method according to claim 48, the method comprising administering to a person in need of treatment for a psychoses, a therapeutically effective amount of:


- (a) (1*S*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide



- (b) (1*R*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide




- (c) (1*S*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide



- (d) (1*R*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-

tetrahydronaphthalen-1-yl]formamide



- (e) a mixture of **A** and **B**;
- (f) a mixture of **C** and **D**; or
- (g) a pharmaceutically acceptable salt thereof, together with
- (h) a therapeutically effective amount of a D<sub>2</sub> antagonist, or a pharmaceutically acceptable salt thereof.

50. (previously added) The method according to claim 48, wherein the D<sub>2</sub> antagonist is olanzapine.


51. (cancelled)

52. (cancelled)


53. (previously added) A method for treating psychoses in a human, the method comprising administering to a person in need of treatment for a psychoses, a therapeutically effective amount of *N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide.

54. (currently amended) A method according to claim 53, the method comprising administering to a person in need of treatment for a psychoses, a therapeutically effective amount of:


- (a) (1*S*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide




- (b) (1*R*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide



- (c) (1*S*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide



- (d) (1*R*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide



- (e) a mixture of **A** and **B**;
- (f) a mixture of **C** and **D**; or
- (g) a pharmaceutically acceptable salt thereof, together with
- (h) a therapeutically effective amount of an ~~atypical~~ antipsychotic agent, or a pharmaceutically acceptable salt thereof.

55. (previously added) A process for preparing *N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide comprising reacting 4-(3,4-dichlorophenyl)-3,4-dihydro-1-naphthalenone with an excess of formic acid and formamide to provide *N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide.

56. (previously added) The process according to claim 55, wherein the 4-(3,4-dichlorophenyl)-3,4-dihydro-1-naphthalenone is of the (*S*) configuration and the *N*-[4-(3,4-dichloro phenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide is a 1:1 mixture of (1*R*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide and (1*S*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide.

57. (previously added) The process according to claim 56, further comprising separating the (1*R*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide and (1*S*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl] formamide.

58. (previously added) The process according to claim 55, wherein the 4-(3,4-dichlorophenyl)-3,4-dihydro-1-naphthalenone is of the (*R*) configuration and the *N*-[4-(3,4-dichloro phenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide is a 1:1 mixture of (1*R*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide and (1*S*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide.

59. (previously added) The process according to claim 58, further comprising separating the (1*R*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-

yl]formamide and (1*S*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl] formamide.

60. (previously added) The process according to claim 55, wherein the 4-(3,4-dichlorophenyl)-3,4-dihydro-1-naphthalenone is racemic and the process further comprises separating the *N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl] formamide into *cis N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl] formamide and *trans N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide.